FDA 503A Category 2 Peptide Reclassification (2026): What Researchers Need to Know
TL;DR: In April 2026 the FDA removed BPC-157, TB-500, MOTS-c, Semax & 8 more peptides from its 503A Category 2 list. PCAC review: July 2026.
What Was FDA 503A Category 2?
To understand the 2026 reclassification, it helps to know what Category 2 meant. Under Section 503A of the US Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare individualised preparations for patients, but the FDA maintains two lists relevant to which substances they may use. Category 1 substances are permitted for compounding; Category 2 substances are nominated for restrictions, meaning that while they are being evaluated, their use in compounding preparations is effectively prohibited pending a formal Committee ruling.[1]
Between 2023 and 2024, the FDA placed 19 peptides on the 503A Category 2 list — a move that drew significant criticism from compounding pharmacies, researchers, and clinician groups who argued the process bypassed normal administrative procedures. The Category 2 placements effectively froze US pharmacy compounding of those peptides while the FDA's Pharmacy Compounding Advisory Committee (PCAC) was scheduled to review them.[2]
What Changed in February–April 2026?
The reclassification originated with a public announcement by US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on 27 February 2026, in which he stated that most of the peptides on the 503A Category 2 list would be reconsidered for reclassification back to Category 1.[3]
The mechanism used was procedurally significant: the nominations that originally placed the peptides on Category 2 were withdrawn. Under 503A rules, a substance can only remain on Category 2 if it has an active nomination under consideration. With the nominations withdrawn, 12 of the 19 peptides had no basis to remain on Category 2 and were formally removed effective 15 April 2026.[4]
HHS Secretary Kennedy confirmed the formal withdrawal of Category 2 nominations for 12 peptide substances. Withdrawal of the nomination removed each compound from the Category 2 list. The change did not confer Category 1 status; individual PCAC review is required before compounding is formally cleared. The remaining 7 of the original 19 Category 2 peptides were not affected and remain under review.
Source: SSRP Institute, April 2026 · BioPharma Dive
Which 12 Peptides Were Removed from Category 2?
The following 12 peptides had their Category 2 nominations withdrawn and were removed from the 503A Category 2 list as of April 2026. Several are compounds Velox Peptides stocks as research reagents.
| Peptide | Also known as | Research category | Velox stock |
|---|---|---|---|
| BPC-157 | Body Protection Compound-157 | Tissue repair research | ✓ In stock |
| TB-500 | Thymosin β-4 fragment | Recovery research | ✓ In stock |
| MOTS-c | Mitochondrial-derived peptide | Metabolic research | ✓ In stock |
| Semax | ACTH(4–7)-Pro-Gly-Pro | Cognitive research | ✓ In stock |
| DSIP | Emideltide / Delta Sleep-Inducing Peptide | Neuropeptide research | ✓ In stock |
| GHK-Cu | Copper tripeptide (injectable form) | Skin & tissue research | ✓ In stock |
| KPV | Lys-Pro-Val | Anti-inflammatory research | ✓ In stock |
| Epitalon | Epithalon / Epithalamin tetrapeptide | Anti-ageing research | ✓ In stock |
| Melanotan II | MT-II | Melanocortin research | ✓ In stock |
| PEG-MGF | Pegylated Mechano Growth Factor | Growth factor research | ✗ Not stocked |
| LL-37 | Cathelicidin antimicrobial peptide | Antimicrobial research | ✗ Not stocked |
| DiHexa | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Cognitive research | ✗ Not stocked |
Note: GHK-Cu removal from Category 2 applies specifically to the injectable form; topical formulations were not classified in the same way. Source: PeptideWise, 2026; SSRP Institute.
What Does Removal from Category 2 Mean — and Not Mean?
The distinction here is one of the most misreported aspects of the 2026 changes. A Pharmacy Times analysis from a clinical pharmacist perspective summarised the situation clearly: removal from Category 2 is a procedural step, not an approval.[5]
What it DOES mean
These 12 peptides are no longer on the FDA's list of substances that cannot be compounded under 503A. The prohibition on their use in licensed US compounding pharmacy preparations has been lifted pending PCAC review. Compounding pharmacies in the US may have greater flexibility in how they handle these substances than they did under Category 2 restrictions.
What it does NOT mean
Removal from Category 2 does not mean the FDA has approved these peptides as medicines. It does not grant Category 1 status automatically — that requires a separate PCAC vote. It does not change the status of these compounds as unapproved drugs. None of these substances has received FDA approval for any indication.
Not an FDA drug approval
The 503A compounding list system is entirely separate from the drug-approval pathway (NDA/BLA). A compound moving off Category 2 is a regulatory housekeeping action affecting compounding pharmacies only. It has no bearing on clinical approval, marketing authorisation, or legitimate research-reagent supply.
What Is the July 2026 PCAC Review?
The FDA's Pharmacy Compounding Advisory Committee is scheduled to convene on 23–24 July 2026 to formally evaluate the first batch of de-listed peptides for potential Category 1 placement.[1][6] Category 1 designation is what would formally permit licensed compounding pharmacies in the US to use a substance in 503A preparations.
The first-batch peptides under PCAC review in July 2026 are:
- BPC-157
- TB-500
- MOTS-c
- Semax
- DSIP (Emideltide)
- Epitalon
- KPV
The remaining de-listed peptides (GHK-Cu injectable, Melanotan II, PEG-MGF, LL-37, DiHexa) are expected to be evaluated in subsequent PCAC sessions. The FDA is not required to follow PCAC recommendations, but the committee's decisions typically inform subsequent regulatory guidance and enforcement posture.
What Does This Mean for UK Researchers?
The FDA's 503A compounding framework is a US-specific regulatory system. It applies to licensed US compounding pharmacies operating under federal law, and has no direct legal force in the United Kingdom. UK regulation of medicines and research reagents is administered separately by the Medicines and Healthcare products Regulatory Agency (MHRA) under the Human Medicines Regulations 2012.
For UK-based researchers purchasing compounds like BPC-157, TB-500, Semax, MOTS-c, GHK-Cu, DSIP or KPV as research reagents, the UK legal position is governed by UK law, not FDA classifications. These compounds are not scheduled controlled substances under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016. They are supplied by Velox Peptides as research reagents for in vitro laboratory research use only, under our Research Use Policy.
The FDA reclassification is nonetheless relevant context for UK researchers: it reflects the evolving global regulatory landscape for this class of compounds, and the PCAC review process will generate new published safety and characterisation data that may inform future research directions. Our guide on whether research peptides are legal in the UK covers the UK-specific position in more detail.
References
- BioPharma Dive. FDA moves toward easing restrictions on certain peptides. April 2026. biopharmadive.com
- BSCG. What's Changing With Peptide Regulation in 2026. 2026. bscg.org
- OpenLoop Health. What Peptides Are Becoming Legal in 2026? 2026. openloophealth.com
- SSRP Institute. FDA Announces Change in Status of 12 Peptides. April 2026. ssrpinstitute.org
- Pharmacy Times. The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take. 2026. pharmacytimes.com
- PeptideWise. FDA Peptide Reclassification 2026: 503A List Full Update. 2026. getpeptidewise.com
Frequently Asked Questions
Which peptides were removed from FDA 503A Category 2 in 2026?
On 15 April 2026, HHS confirmed the removal of 12 peptides from FDA 503A Category 2: BPC-157, LL-37, DiHexa, DSIP (Emideltide), Epitalon, GHK-Cu (injectable), KPV, PEG-MGF, Melanotan II, MOTS-C, Semax, and TB-500. Their nominations to Category 2 were withdrawn, triggering their formal removal.
What does removal from FDA Category 2 mean?
Removal from 503A Category 2 means these peptides are no longer on the FDA's list of substances that cannot be compounded under section 503A. However, removal does not automatically grant Category 1 status or confirm that compounding is legally permitted — each substance still requires individual review by the FDA's Pharmacy Compounding Advisory Committee (PCAC) before compounding is formally cleared.
When is the PCAC meeting to review these peptides?
The FDA's Pharmacy Compounding Advisory Committee is scheduled to meet on 23–24 July 2026. The first batch under review includes BPC-157, KPV, MOTS-c, Emideltide (DSIP), Epitalon, Semax, and TB-500.
Does the FDA reclassification affect UK researchers?
The FDA's 503A Category 2 system governs US compounding pharmacies only. UK researchers purchasing research-use peptides from Velox Peptides operate under UK law and MHRA regulation, which are entirely independent of FDA classifications. The UK legal status of research-use peptides is governed by UK legislation and is unchanged by the US reclassification.
Are BPC-157 and TB-500 legal research peptides in the UK?
BPC-157 and TB-500 are not licensed medicines in the UK and are not scheduled controlled substances under UK law. They are supplied by Velox Peptides strictly as research reagents for in vitro laboratory research only, in accordance with our Research Use Policy and MHRA Statement.
What happens after the July 2026 PCAC meeting?
The PCAC will evaluate each peptide in the first review batch and make recommendations to the FDA on whether they should be permitted for compounding under 503A. The FDA is not required to follow PCAC recommendations, but committee decisions typically inform subsequent regulatory guidance. Further batches of peptides are expected to be reviewed in subsequent PCAC sessions later in 2026.
